Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 0

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-271073

Prospectus supplement
(To Prospectus dated April 13, 2023)

<div align='center'>Alpha Tau Medical Ltd.

14,110,121 Ordinary Shares</div>

We are offering 14,110,121 ordinary shares, no
par value (“ordinary shares”) to an accredited investor (the “Investor”) pursuant to this prospectus supplement
and the accompanying prospectus and a share purchase agreement, dated April 24, 2025, between us and the Investor (the “purchase
agreement”). The purchase price of each Ordinary Share is $2.612, which represents the volume weighted average closing price of
our ordinary shares in the eight trading days prior to the execution of the share purchase agreement.

Our ordinary shares and warrants are listed on
the Nasdaq Stock Market LLC under the trading symbols “DRTS” and “DRTSW,” respectively. On April 23, 2025, the
closing prices for our ordinary shares and warrants on the Nasdaq Stock Market LLC were $2.67 per ordinary share and $0.23 per warrant.

We are an “emerging growth company”
and a “foreign private issuer” as defined under the U.S. Securities and Exchange Commission, or the SEC, and, as such,
we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See “Prospectus
Supplement Summary—Implications of Being an Emerging Growth Company” and “Prospectus Supplement Summary—Implications
of Being a Foreign Private Issuer.”

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-7of this prospectus supplement, in the accompanying prospectus and under similar headings in the documents incorporated by reference into this prospectus supplement, and the accompanying prospectus to read about factors you should consider before buying our securities.

None of the Securities and Exchange Commission, the Israel Securities Authority or any other regulatory body or state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

We expect to deliver the securities to the Investor
on or about April 28, 2025, subject to the satisfaction of customary closing conditions.

<div align='center'>Prospectus supplement dated April 24, 2025.

TABLE